Interim Analysis Of A Phase I Single-Arm Study Of The Combination Of Durvalumab (Medi4736) And Vicinium (Oportuzumab Monatox, Vb4-845) In Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (Bcg) (Nct03258593)